Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma

Next Previous
Search
Trial Profile

Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zevorcabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 14 Dec 2021 Results of pooled analysis from NCT03380039, NCT03716856, NCT03302403 and NCT03975907; assessing efficacy and safety of CT053 in Chinese subjects with Relapsed and Refractory Multiple Myeloma based on high-risk factors, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 08 Dec 2020 Results (n=24) reporting safety and efficacy of CT053 from pooled data of three phase I, investigator-initiated program (NCT03716856, NCT03302403, and NCT03380039) in China at two year follow-up presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2020 Results presented in a CARsgen media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top